Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AHR | P35869 | 1/20 | 0.37 |
| ▸ | TNF | P01375 | 1/20 | 0.35 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.35 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.32 |
| ▸ | EGFR | P00533 | 1/20 | 0.30 |
| ▸ | BRD4 | O60885 | 1/20 | 0.30 |
| ▸ | TAF1 | P21675 | 1/20 | 0.30 |
| ▸ | BRPF1 | P55201 | 1/20 | 0.30 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.30 |
| ▸ | CECR2 | Q9BXF3 | 1/20 | 0.30 |
| ▸ | BRD9 | Q9H8M2 | 1/20 | 0.30 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL427782 | 0.80 | AHR (0.36) | AHR | |
| SCHEMBL2150779 | 0.78 | TNF (0.35) | AHRTNFRIPK1PIM3EGFR | |
| SCHEMBL3085133 | 0.74 | KDM4A (0.33) | PIM3 | |
| SCHEMBL450386 | 0.73 | EGFR (0.40) | AHRTNFRIPK1EGFR | |
| Urea SCHEMBL1549376 | 0.73 | CCNA2 (0.43) | — | |
| SCHEMBL16896218 | 0.71 | EGFR (0.39) | AHRTNFRIPK1EGFR | |
| SCHEMBL7744423 | 0.71 | AHR (0.35) | AHRTNFRIPK1PIM3 | |
| SCHEMBL4538052 | 0.70 | AOC3 (0.32) | — | |
| SCHEMBL1233929 | 0.69 | CCNA2 (0.37) | — | |
| SCHEMBL167198 | 0.69 | CCNA2 (0.31) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0802198-A2 | Pyridazino-, pyrimido, pyrazino and triazino-indoles | BAYER AG (DE) | 1997-10-22 | — | — | EP | claimed |
| US-20230183249-A1 | NEW TRIAZINOINDOLE COMPOUNDS | JANSSEN PHARMACEUTICA NV (BE) | 2023-06-15 | — | — | US | disclosed |
| EP-4143192-A1 | NEW TRIAZINOINDOLE COMPOUNDS | JANSSEN Pharmaceutica NV (BE) | 2023-03-08 | — | — | EP | disclosed |
| EP-4143192-A1 | NEW TRIAZINOINDOLE COMPOUNDS | JANSSEN Pharmaceutica NV (BE) | 2023-03-08 | — | — | EP | disclosed |
| WO-2023277341-A1 | ANTIVIRAL AGENT INCLUDING TRIAZINOINDOLE DERIVATIVE AS ACTIVE INGREDIENT | 재단법인 대구경북첨단의료산업진흥재단 | 2023-01-05 | — | — | WO | disclosed |
| WO-2023277341-A1 | ANTIVIRAL AGENT INCLUDING TRIAZINOINDOLE DERIVATIVE AS ACTIVE INGREDIENT | 재단법인 대구경북첨단의료산업진흥재단 | 2023-01-05 | — | — | WO | disclosed |
| WO-2023277341-A1 | ANTIVIRAL AGENT INCLUDING TRIAZINOINDOLE DERIVATIVE AS ACTIVE INGREDIENT | 재단법인 대구경북첨단의료산업진흥재단 | 2023-01-05 | — | — | WO | disclosed |
| CN-115485280-A | Novel triazinoindole compounds | 詹森药业有限公司 | 2022-12-16 | — | — | CN | disclosed |
| CN-115485280-A | Novel triazinoindole compounds | 詹森药业有限公司 | 2022-12-16 | — | — | CN | disclosed |
| US-20170079252-A1 | NOVEL GERM CELL ABLATION COMPOUNDS AND USES THEREOF | THE GENERAL HOSPITAL CORPORATION (US) | 2017-03-23 | — | — | US | disclosed |
| US-9538734-B2 | Germ cell ablation compounds and uses thereof | THE GENERAL HOSPITAL CORPORATION (US) | 2017-01-10 | — | — | US | disclosed |
| US-20140261212-A1 | NOVEL GERM CELL ABLATION COMPOUNDS AND USES THEREOF | THE GENERAL HOSPITAL CORPORATION (US) | 2014-09-18 | — | — | US | disclosed |
| EP-0802198-A3 | Pyridazino-, pyrimido, pyrazino and triazino-indoles | BAYER AG (DE) | 1998-04-15 | — | — | EP | disclosed |
| EP-0802198-A3 | Pyridazino-, pyrimido, pyrazino and triazino-indoles | BAYER AG (DE) | 1998-04-15 | — | — | EP | disclosed |
| EP-0802198-A2 | Pyridazino-, pyrimido, pyrazino and triazino-indoles | BAYER AG (DE) | 1997-10-22 | — | — | EP | disclosed |
| EP-0802198-A2 | Pyridazino-, pyrimido, pyrazino and triazino-indoles | BAYER AG (DE) | 1997-10-22 | — | — | EP | disclosed |
| EP-0802198-A2 | Pyridazino-, pyrimido, pyrazino and triazino-indoles | BAYER AG (DE) | 1997-10-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170079252-A1 | NOVEL GERM CELL ABLATION COMPOUNDS AND USES THEREOF | ALPG, PROX1, SOX18 | AHR 2160/4885TNF 4804/4885RIPK1 2543/4885 |
| US-20230183249-A1 | NEW TRIAZINOINDOLE COMPOUNDS | NLRP3, NLRP1, PYCARD | AHR 1496/4885TNF 537/4885RIPK1 138/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.